171 related articles for article (PubMed ID: 33945619)
1. Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.
Marcault C; Zhao LP; Maslah N; Verger E; Daltro de Oliveira R; Soret-Dulphy J; Cazaux M; Gauthier N; Roux B; Clappier E; Parquet N; Dosquet C; Réa D; Zini JM; Vainchenker W; Raffoux E; Giraudier S; Kiladjian JJ; Cassinat B; Benajiba L
Blood; 2021 Nov; 138(21):2142-2148. PubMed ID: 33945619
[No Abstract] [Full Text] [Related]
2. Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms.
Guglielmelli P; Pacilli A; Coltro G; Mannelli F; Mannelli L; Contini E; Rotunno G; Bartalucci N; Fiaccabrino S; Sordi B; Loscocco GG; Paoli C; Vannucchi AM
Am J Hematol; 2020 Jan; 95(1):E23-E26. PubMed ID: 31659782
[No Abstract] [Full Text] [Related]
3. The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2
Staehle AM; Peeken JC; Vladimirov G; Hoeness ME; Bojtine Kovacs S; Karantzelis N; Gruender A; Koellerer C; Jutzi JS; Pahl HL; Staehle HF
Leukemia; 2023 Apr; 37(4):919-923. PubMed ID: 36709354
[TBL] [Abstract][Full Text] [Related]
4. Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Jutzi JS; Basu T; Pellmann M; Kaiser S; Steinemann D; Sanders MA; Hinai ASA; Zeilemaker A; Bojtine Kovacs S; Koellerer C; Ostendorp J; Aumann K; Wang W; Raffoux E; Cassinat B; Bullinger L; Schlegelberger B; Valk PJM; Pahl HL
Blood; 2019 Apr; 133(16):1766-1777. PubMed ID: 30755419
[TBL] [Abstract][Full Text] [Related]
5. The transcription factor NFE2 enhances expression of the hematopoietic master regulators SCL/TAL1 and GATA2.
Siegwart LC; Schwemmers S; Wehrle J; Koellerer C; Seeger T; Gründer A; Pahl HL
Exp Hematol; 2020 Jul; 87():42-47.e1. PubMed ID: 32593672
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.
Peeken JC; Jutzi JS; Wehrle J; Koellerer C; Staehle HF; Becker H; Schoenwandt E; Seeger TS; Schanne DH; Gothwal M; Ott CJ; Gründer A; Pahl HL
Blood; 2018 May; 131(18):2065-2073. PubMed ID: 29519804
[TBL] [Abstract][Full Text] [Related]
7. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
[TBL] [Abstract][Full Text] [Related]
8. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.
Jutzi JS; Bogeska R; Nikoloski G; Schmid CA; Seeger TS; Stegelmann F; Schwemmers S; Gründer A; Peeken JC; Gothwal M; Wehrle J; Aumann K; Hamdi K; Dierks C; Kamar Wang W; Döhner K; Jansen JH; Pahl HL
J Exp Med; 2013 May; 210(5):1003-19. PubMed ID: 23589569
[TBL] [Abstract][Full Text] [Related]
9. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.
Wang W; Schwemmers S; Hexner EO; Pahl HL
Blood; 2010 Jul; 116(2):254-66. PubMed ID: 20339092
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
[No Abstract] [Full Text] [Related]
12. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
13. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
14. Isolated myelosarcoma is characterized by recurrent
Lazarevic V; Orsmark-Pietras C; Lilljebjörn H; Pettersson L; Rissler M; Lübking A; Ehinger M; Juliusson G; Fioretos T
Blood; 2018 Feb; 131(5):577-581. PubMed ID: 29191917
[No Abstract] [Full Text] [Related]
15. RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling.
Kapralova K; Lanikova L; Lorenzo F; Song J; Horvathova M; Divoky V; Prchal JT
Blood; 2014 Jan; 123(3):391-4. PubMed ID: 24297870
[TBL] [Abstract][Full Text] [Related]
16. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
[No Abstract] [Full Text] [Related]
17. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
18. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
[TBL] [Abstract][Full Text] [Related]
19. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
20. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Kubesova B; Pavlova S; Malcikova J; Kabathova J; Radova L; Tom N; Tichy B; Plevova K; Kantorova B; Fiedorova K; Slavikova M; Bystry V; Kissova J; Gisslinger B; Gisslinger H; Penka M; Mayer J; Kralovics R; Pospisilova S; Doubek M
Leukemia; 2018 Feb; 32(2):450-461. PubMed ID: 28744014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
